FF301 本月底法定/註冊股本總額： RMB 144,707,176 | | | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中生北控生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年12月1日 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08247 | 說明 | H股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 64,286,143 | | 0 | | 64,286,143 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 64,286,143 | | 0 | | ...

Key Points - A total of 45 stocks reached their 52-week highs as of the market close on November 17, with notable performers including China National Biotech Group (08247), Doumeng Technology (01917), and Century United Holdings (01959) achieving high rates of 55.17%, 48.72%, and 33.70% respectively [1] - The highest closing prices for the top three stocks were 1.700, 0.099, and 2.270, with their peak prices being 1.800, 0.116, and 2.420 respectively [1] - Other significant stocks that reached new highs include Jingyang Group (08257) with a high rate of 27.66% and Hongji Group Holdings (01718) at 22.22% [1] - The report also highlights stocks that reached their 52-week lows, with Starry Chain Group (00399) experiencing a significant decline of 59.31% [2] - Other notable decliners include Xingkong Huawen (06698) and Limo Technology (02405) with declines of 13.79% and 13.46% respectively [2] - The data indicates a mixed performance in the market, with some stocks achieving significant gains while others faced substantial losses [2][3]

FF301 | | | | IVE | | | | --- | --- | --- | | X | | | | | ILINE | | | 港 交 易 所 | 香 | | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中生北控生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08247 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 64,286,143 | RMB | | 1 RMB | | 64,286,143 | | 增加 / 減少 (-) | | | ...

FF301 致：香港交易及結算所有限公司 | | | | 2. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 80,421,033 | RMB | | 1 RMB | | 80,421,033 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 80,421,033 | RMB | | 1 RMB | | 80,421,033 | 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- ...

Core Viewpoint - The article discusses the evolving landscape of the medical device industry in China, highlighting the importance of business development (BD) strategies that go beyond mere numbers to encompass strategic partnerships, market expansion, and technological integration [1][24]. Group 1: Key Trends in Medical Device BD - The primary keywords for the period from July to September include cross-border introduction and global distribution, strategic cooperation, and capital and cross-industry integration [2]. - Companies are accelerating market expansion and ecosystem building through transactions across various fields, including cardiovascular, neuro-intervention, ophthalmology, IVD, and critical care [3]. Group 2: Representative Events - A total of 20 significant events were summarized, showcasing a "multi-line advancement" scenario in the industry [4]. - Notable collaborations include: - Nanjing Jianxin Medical and Heqi Family Office focusing on medical device R&D and wealth management [6]. - Olympus and Xingchenhai Medical signing a global distribution agreement for disposable urology products [6]. - He’s Eye Group and Zeiss China Medical forming a strategic partnership to enhance ophthalmic surgical technology [6]. Group 3: Cross-Border and Global Distribution - Cross-border transactions remain a hot topic, with domestic companies leveraging global markets for growth while foreign giants introduce Chinese innovations [9]. - The partnership between Ruichao Dinkai Group and Beijing Amite focuses on vascular intervention products, marking a new phase in safety standards [7]. Group 4: Strategic Cooperation and Channel Expansion - Strategic cooperation is increasingly focused on building ecosystems rather than single product breakthroughs, with companies forming partnerships in fields like ophthalmology, IVD, and diagnostics [19]. - The collaboration between Wanfu Biological and Beiden Medical aims to match products with non-public medical channels effectively [15]. Group 5: Capital Support and Cross-Industry Integration - Capital is becoming an invisible driver of medical device BD, with partnerships exploring new models for medical device distribution [20]. - The collaboration between Beijing Huamai Supply Chain Management and Hongyi Consulting aims to create a one-stop service for medical device distribution [20]. Group 6: Smart Hospitals and Full-Chain Coordination - The focus on smart hospitals and full-chain coordination is becoming a priority for large enterprises, integrating supply chains, academic promotion, and clinical needs [23]. - Collaborations like that of Ruibo Zehou Technology and China National Pharmaceutical Group aim to develop automated systems for smart hospitals [21]. Conclusion - The medical device industry in China is transitioning from a "single product-driven" phase to a more diversified approach supported by capital, channels, and ecosystems, indicating a long-term growth trajectory [24].

| | | | 2. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 80,421,033 | RMB | | 1 RMB | | 80,421,033 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 80,421,033 | RMB | | 1 RMB | | 80,421,033 | FF301 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08247 | 說明 | H股 ...

中生北控生物科技(08247)发布截至2025年6月30日止6个月中期业绩，集团营业收入人民币9581.5万元， 同比减少28.4%;股东应占亏损1797.6万元，同比扩大36.37%;每股亏损0.124元。 ...

智通财经APP讯，中生北控生物科技(08247)发布截至2025年6月30日止6个月中期业绩，集团营业收入人 民币9581.5万元，同比减少28.4%;股东应占亏损1797.6万元，同比扩大36.37%;每股亏损0.124元。 ...

提名委員會職權範圍及程序 定義 | 董事會 | 指本公司的董事會 | | --- | --- | | 本公司 | 指中生北控生物科技股份有限公司 | | 董事 | 指本公司的董事 | | 《上市規則》 | 指聯交所GEM《證券上市規則》 | | 本集團 | 指本公司及其附屬公司 | | 獨立非執行董事 | 指本公司的獨立非執行董事 | | 提名委員會 | 指董事會根據本職權範圍及程序通過之決議而成立 | | | 的提名委員會 | | 高級管理人員 | 指本公司的高級管理人員 | | 聯交所 | 指香港聯合交易所有限公司 | 成立提名委員會的目的 董事會成立提名委員會的目的是為了更好地處理有關董事會成員的提名及組成之 事宜，並提高董事會的工作效率。 * 僅供識別 1 利益披露 組成 5. 提名委員會的每一位成員應向提名委員會披露其在由提名委員會決定的任何 事項中享有的任何個人財務利益，及涉及其的因該等事項引發的任何潛在利 益衝突。任何享有該等利益或涉及該等潛在利益衝突的成員應回避與該等利 益或潛在利益衝突有關的提名委員會決議的表決、回避參與涉及該等決議的 任何討論，若董事會要求，有關成員應向提名委員會請辭。 會 ...

NOTIFICATION LETTER 通知信函 29 August 2025 Dear Non-registered Shareholder(s) (Note 1) , Biosino Bio-Technology and Science Incorporation (the "Company") – Notification of publication of Interim Report 2025 (the "Current Corporate Communication") Yours faithfully, For and on behalf of the Board Biosino Bio-Technology and Science Incorporation Tung Woon Cheung, Eric Company Secretary Notes: 各位非登記股東 （附註1） ： 中生北控生物科技股份有限公司（「本公司」） －2025年中期報告（「本次公司通訊」）之發佈通知 本 公 司 的 本 次 公 司 通 訊 之 中、英 文 版 本 已 分 別 上 載 於 本 公 司 網 站 (www ...